Did You Miss Calithera Biosciences's (NASDAQ:CALA) 37% Share Price Gain?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!
While Calithera Biosciences, Inc. (NASDAQ:CALA) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 13% in the last quarter. But at least the stock is up over the last three years. In that time, it is up 37%, which isn't bad, but not amazing either.
View our latest analysis for Calithera Biosciences
Calithera Biosciences isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
Depicted in the graphic below, you'll see revenue and earnings over time. If you want more detail, you can click on the chart itself.
Take a more thorough look at Calithera Biosciences's financial health with this free report on its balance sheet.
A Different Perspective
It's nice to see that Calithera Biosciences shareholders have gained 17% (in total) over the last year. That's better than the annualized TSR of 11% over the last three years. These improved returns may hint at some real business momentum, implying that now could be a great time to delve deeper. You could get a better understanding of Calithera Biosciences's growth by checking out this more detailed historical graph of earnings, revenue and cash flow.
We will like Calithera Biosciences better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.
